1.55  -0.04 (-2.52%)		06-18 10:37
Open: 1.64 High: 1.64 Volume: 49,839		Pre. Close: 1.59 Low: 1.53 Market Cap: 61(M)

Short term
Mid term
Targets	6-month :	2.83	1-year :	3.67
Resists	First :	2.42	Second :	3.15
Pivot price	1.96
Supports	First :	1.25	Second :	1.04
MAs	MA(5) :	1.53	MA(20) :	2.18
	MA(100) :	3.31	MA(250) :	4.81
MACD	MACD :	-0.5	Signal :	-0.4
%K %D	K(14,3) :	18.1	D(3) :	16.4
RSI	RSI(14): 31.1
52-week	High :	8.58	Low :	1.25

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ NYXH ] has closed above bottom band by 36.8%. Bollinger Bands are 184.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	1.69 - 1.7	1.7 - 1.71
Low:	1.56 - 1.57	1.57 - 1.58
Close:	1.58 - 1.59	1.59 - 1.6

Nyxoah S.A. is a medical technology company dedicated to developing and bringing to market therapies for sleep disordered breathing conditions. Its flagship offering is the Genio system, a CE-Marked, patient-focused hypoglossal neurostimulation therapy that addresses moderate to severe obstructive sleep apnea. Established in 2009, the company maintains its headquarters in Mont-Saint-Guibert, Belgium.

Wed, 17 Jun 2026
Nyxoah SA (NYXH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Wed, 17 Jun 2026
Publication relating to transparency notifications - Yahoo! Finance Canada

Wed, 17 Jun 2026
Publication relating to transparency notifications - GlobeNewswire

Wed, 17 Jun 2026
Nyxoah gets four transparency notices as holders move above and below thresholds - Stock Titan

Wed, 17 Jun 2026
Nyxoah taps another $15M as it readies Genio U.S. launch - Stock Titan

Wed, 17 Jun 2026
Nyxoah Receives $15 Million from the European Investment Bank - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	100 (M)
Shares Float	24 (M)
Held by Insiders	16.1 (%)
Held by Institutions	9.5 (%)
Shares Short	425 (K)
Shares Short P.Month	326 (K)

EPS	-2.47
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.94
Profit Margin	0 %
Operating Margin	-321.8 %
Return on Assets (ttm)	-44.6 %
Return on Equity (ttm)	-130 %
Qtrly Rev. Growth	498.8 %
Gross Profit (p.s.)	0.09
Sales Per Share	0.15
EBITDA (p.s.)	-0.83
Qtrly Earnings Growth	0 %
Operating Cash Flow	-72 (M)
Levered Free Cash Flow	-46 (M)

PE Ratio	-0.65
PEG Ratio	0
Price to Book value	1.67
Price to Sales	10.36
Price to Cash Flow	-2.21

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.